Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer

Abstract

Background: Bladder cancer (BLCA) is a common malignant tumor of the genitourinary system, and there is a lack of specific, reliable, and non-invasive tumor biomarker tests for diagnosis and prognosis evaluation. Homeobox genes play a vital role in BLCA tumorigenesis and development, but few studies have focused on the prognostic value of homeobox genes in BLCA. In this study, we aim to develop a prognostic signature associated with the homeobox gene family for BLCA.Methods: The RNA sequencing data, clinical data, and probe annotation files of BLCA patients were downloaded from the Gene Expression Omnibus database and the University of California, Santa Cruz (UCSC), Xena Browser. First, differentially expressed homeobox gene screening between tumor and normal samples was performed using the “limma” and robust rank aggregation (RRA) methods. The mutation data were obtained with the “TCGAmutation” package and visualized with the “maftools” package. Kaplan–Meier curves were plotted with the “survminer” package. Then, a signature was constructed by logistic regression analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using “clusterProfiler.” Furthermore, the infiltration level of each immune cell type was estimated using the single-sample gene set enrichment analysis (ssGSEA) algorithm. Finally, the performance of the signature was evaluated by receiver-operating characteristic (ROC) curve and calibration curve analyses.Results: Six genes were selected to construct this prognostic model: TSHZ3, ZFHX4, ZEB2, MEIS1, ISL1, and HOXC4. We divided the BLCA cohort into high- and low-risk groups based on the median risk score calculated with the novel signature. The overall survival (OS) rate of the high-risk group was significantly lower than that of the low-risk group. The infiltration levels of almost all immune cells were significantly higher in the high-risk group than in the low-risk group. The average risk score for the group that responded to immunotherapy was significantly lower than that of the group that did not.Conclusion: We constructed a risk prediction signature with six homeobox genes, which showed good accuracy and consistency in predicting the patient’s prognosis and response to immunotherapy. Therefore, this signature can be a potential biomarker and treatment target for BLCA patients.

The Effects of Differentially-Expressed Homeobox Family Genes on the Prognosis and HOXC6 on Immune Microenvironment Orchestration in Colorectal Cancer

“…Although the prognostic value of HOX family genes has already been explored in bladder cancer ( 26 ) and laryngeal squamous cell cancer ( 27 ), this was the first systemic prognostic study in CRC. More importantly, it was found for the first time that in CRC, the high expression of HOXC6 was significantly related to the remodeling of the TME, including chemokine expression level, immune cell infiltration ratio, immune checkpoint expression level, TMB score, and MSI-H status.…”

Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer

“…Clinical variables included age, gender, T-stage and N-stage. In addition, Kaplan-Meier analyses obtained by the “survival” and “survminer” software packages were used to assess differences in OS between the different modalities ( 14 ).…”

18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

“…The differences between two groups were analyzed by an unpaired Student's t-test using GraphPad Prism 8.0 software (USA). FGFR4-HK2 signature score was determined by Cox model 36 . Briefly, this score of each patient was calculated as follows: FGFR4-HK2 signature score = X FGFR4 β FGFR4 + X HK2 β HK2 (X and β indicated the mRNA level and the risk coefficient of Cox model by survival analysis in R version 3.5.3, respectively).…”